X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2709) 2709
Publication (389) 389
Book Review (67) 67
Newsletter (51) 51
Newspaper Article (9) 9
Book Chapter (7) 7
Magazine Article (5) 5
Data Set (3) 3
Conference Proceeding (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bortezomib (2428) 2428
humans (2155) 2155
index medicus (1791) 1791
male (1228) 1228
multiple myeloma (1199) 1199
multiple myeloma - drug therapy (1188) 1188
female (1180) 1180
oncology (1174) 1174
middle aged (1108) 1108
hematology (1054) 1054
aged (1050) 1050
treatment outcome (719) 719
antineoplastic combined chemotherapy protocols - therapeutic use (708) 708
adult (707) 707
boronic acids - adverse effects (676) 676
pyrazines - adverse effects (674) 674
boronic acids - administration & dosage (570) 570
antineoplastic agents - adverse effects (569) 569
pyrazines - administration & dosage (569) 569
antineoplastic agents - therapeutic use (563) 563
dexamethasone (545) 545
antineoplastic combined chemotherapy protocols - adverse effects (531) 531
boronic acids - therapeutic use (490) 490
pyrazines - therapeutic use (488) 488
therapy (472) 472
cancer (470) 470
care and treatment (444) 444
aged, 80 and over (440) 440
chemotherapy (428) 428
lenalidomide (402) 402
dexamethasone - administration & dosage (385) 385
thalidomide (383) 383
stem-cell transplantation (373) 373
drug therapy (345) 345
survival (329) 329
thalidomide - analogs & derivatives (324) 324
research (309) 309
multiple myeloma - mortality (301) 301
transplantation (298) 298
multiple-myeloma (294) 294
recurrence (294) 294
thalidomide - administration & dosage (292) 292
animals (290) 290
multiple myeloma - pathology (285) 285
proteasome inhibitors (265) 265
antineoplastic agents - administration & dosage (264) 264
combination (250) 250
disease-free survival (250) 250
thalidomide - adverse effects (242) 242
trial (237) 237
dosage and administration (236) 236
apoptosis (232) 232
pharmacology & pharmacy (231) 231
prognosis (224) 224
multiple myeloma - therapy (222) 222
peripheral neuropathy (219) 219
drug administration schedule (209) 209
retrospective studies (207) 207
proteasome inhibitor bortezomib (206) 206
thalidomide - therapeutic use (204) 204
medicine & public health (202) 202
risk factors (200) 200
health aspects (194) 194
survival analysis (191) 191
complications and side effects (189) 189
dose-response relationship, drug (189) 189
melphalan (189) 189
antineoplastic combined chemotherapy protocols - administration & dosage (187) 187
patients (187) 187
bortezomib - administration & dosage (186) 186
dexamethasone - adverse effects (186) 186
hematology, oncology and palliative medicine (182) 182
multiple myeloma - complications (181) 181
clinical trials (179) 179
hemic and lymphatic diseases (178) 178
peripheral nervous system diseases - chemically induced (174) 174
article (173) 173
antineoplastic agents - pharmacology (172) 172
bortezomib - adverse effects (171) 171
proteasome inhibitor (169) 169
myeloma (166) 166
stem cells (165) 165
multiple myeloma - diagnosis (162) 162
medical research (160) 160
analysis (155) 155
prednisone (153) 153
abridged index medicus (152) 152
carfilzomib (151) 151
cyclophosphamide (150) 150
follow-up studies (149) 149
boronic acids - pharmacology (148) 148
pyrazines - pharmacology (148) 148
patient outcomes (146) 146
drug resistance, neoplasm (145) 145
neoplasm staging (144) 144
transplantation, autologous (140) 140
stem cell transplantation (139) 139
survival rate (139) 139
plus dexamethasone (138) 138
rituximab (136) 136
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2670) 2670
Japanese (42) 42
Chinese (29) 29
Spanish (11) 11
French (9) 9
Russian (5) 5
Czech (4) 4
German (3) 3
Korean (2) 2
Catalan (1) 1
Polish (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Clinical Oncology, ISSN 1759-4774, 10/2009, Volume 6, Issue 10, pp. 596 - 603
Historically, body tissues with a high rate of cell turnover, such as the bone marrow, have been most susceptible to chemotherapy-induced damage. The... 
PHASE-II TRIAL | ONCOLOGY | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | ALBUMIN-BOUND PACLITAXEL | BRAIN-TUMOR CONSORTIUM | ACUTE TRANSIENT ENCEPHALOPATHY | CEREBROSPINAL-FLUID PHARMACOKINETICS | OXALIPLATIN-RELATED NEUROTOXICITY | RECURRENT MALIGNANT GLIOMAS | ANALOG IXABEPILONE BMS-247550 | ADVANCED COLORECTAL-CANCER | Dacarbazine - adverse effects | United States | Humans | Antibodies, Monoclonal - adverse effects | Boronic Acids - adverse effects | Drug Approval | Epothilones - adverse effects | Bevacizumab | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Dacarbazine - analogs & derivatives | Pyrroles - adverse effects | Angiogenesis Inhibitors - adverse effects | United States Food and Drug Administration | Tubulin Modulators - adverse effects | Bortezomib | Clinical Trials as Topic | Imatinib Mesylate | Piperazines - adverse effects | Neoplasms - drug therapy | Neurotoxicity Syndromes - etiology | Indoles - adverse effects | Pyrazines - adverse effects | Pyrimidines - adverse effects | Benzamides | Antineoplastic Agents, Alkylating - adverse effects | Organoplatinum Compounds - adverse effects | Antimitotic agents | Complications and side effects | Nervous system diseases | Patient outcomes | Dosage and administration | Genetic aspects | Research | Antineoplastic agents | Drug therapy | Risk factors | Cancer | Index Medicus
Journal Article
Journal Article
Revista de Chimie, ISSN 0034-7752, 08/2016, Volume 67, Issue 8, pp. 1650 - 1653
Recent years witnessed many changes in the treatment of multiple myeloma due to the development of new therapeutic agents. The choice of initial therapy was... 
Velcade (bortezomib) | Dexamethasone | Myeloma | Biochemical factors | biochemical factors | dexamethasone | PROGNOSIS | CELL TRANSPLANTATION | THALIDOMIDE | ANTITUMOR-ACTIVITY | CHEMISTRY, MULTIDISCIPLINARY | ENGINEERING, CHEMICAL | myeloma | INHIBITION | THERAPY | IN-VIVO | PROTEASOME | LENALIDOMIDE
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 895 - 905
In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than... 
MEDICINE, GENERAL & INTERNAL | PREDNISONE | PLUS DEXAMETHASONE | INDUCTION THERAPY | LENALIDOMIDE | INITIAL TREATMENT | RANDOMIZED CONTROLLED-TRIAL | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
TRIAL | PLUS DEXAMETHASONE | ABNORMALITIES | HIGH-DOSE THERAPY | COMPLETE RESPONSE | DOXORUBICIN | PERIPHERAL NEUROPATHY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | DELETION | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 27 - 38
Journal Article